Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors within the central nervous system, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://julianc329wyz9.wiki-racconti.com/user